AQR Capital Management LLC Has $306.43 Million Stake in BioMarin Pharmaceutical Inc. $BMRN

AQR Capital Management LLC increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 90.7% during the second quarter, Holdings Channel.com reports. The fund owned 5,580,573 shares of the biotechnology company’s stock after buying an additional 2,654,768 shares during the period. AQR Capital Management LLC’s holdings in BioMarin Pharmaceutical were worth $306,429,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in BMRN. V Square Quantitative Management LLC bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth approximately $25,000. Rise Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the 1st quarter valued at about $30,000. Brooklyn Investment Group lifted its stake in shares of BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 540 shares during the period. Hantz Financial Services Inc. boosted its position in shares of BioMarin Pharmaceutical by 480.2% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 874 shares in the last quarter. Finally, Employees Retirement System of Texas acquired a new stake in BioMarin Pharmaceutical during the second quarter worth approximately $58,000. 98.71% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BMRN has been the topic of a number of research analyst reports. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Stifel Nicolaus restated a “hold” rating and set a $61.00 price target (down previously from $73.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, November 6th. Sanford C. Bernstein dropped their price objective on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Royal Bank Of Canada reiterated a “sector perform” rating and set a $66.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Finally, Wells Fargo & Company decreased their target price on shares of BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. Sixteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.61.

BioMarin Pharmaceutical Price Performance

BMRN opened at $53.31 on Friday. The firm has a 50-day moving average price of $53.72 and a 200-day moving average price of $55.77. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $73.51. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $10.24 billion, a price-to-earnings ratio of 20.04, a PEG ratio of 0.88 and a beta of 0.30.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.20). BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The business had revenue of $776.13 million during the quarter, compared to the consensus estimate of $782.42 million. During the same period last year, the business posted $0.91 earnings per share. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Equities analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.